Cayman MAVS Monoclonal Antibody (Clone 7B9)

Mitochondrial antiviral-signaling protein (MAVS) is a mitochondrial membrane-bound adapter protein that initiates antiviral immunity. MAVS is activated upon viral infection by the dsRNA-sensing receptors RIG-I and MDA5 and by mitochondrial reactive oxygen species (ROS). Upon activation, MAVS polymerizes and binds to TANK-binding kinase 1 (TBK1) and IKKε, which form a signaling platform to activate IFN regulatory factor 3 (IRF3) and NF-ĸB, respectively.^, MAVS also mediates recruitment of the NLRP3 inflammasome to the mitochondria and activates caspase-1 to release IL-1β in response to non-crystalline inflammasome activators. Embryonic fibroblasts, peritoneal and bone marrow-derived macrophages (BMDMs), and conventional, but not plasmacytoid, dendritic cells from Mavs^-/- mice exhibit reduced Sendai virus-induced increases in IFN-α and IFN-β secretion. Serum viral titers are increased and survival is decreased in Mavs^-/- mice infected with vesicular stomatitis virus compared with wild-type controls. MAVS-deficient, SLE-prone Fcgr2b^-/- mice have decreased serum levels of antinuclear autoantibodies and increased survival compared with MAVS-expressing Fcgr2b^-/- mice. Aggregates of MAVS and plasma levels of IFN-β and the autoantibodies Sm and UN1RNP are increased in peripheral blood mononuclear cells (PBMCs) isolated from patients with systemic lupus erythematosus (SLE). Caymans MAVS Monoclonal Antibody (Clone 7B9) can be used for ELISA, Immunohistochemistry, and Western blot applications. The antibody recognizes MAVS at 56.5 kDa from human samples.

WARNING This product is not for human or veterinary use.